RU2013136908A - Антитела kil-12/il-23 и их применение - Google Patents
Антитела kil-12/il-23 и их применение Download PDFInfo
- Publication number
- RU2013136908A RU2013136908A RU2013136908/10A RU2013136908A RU2013136908A RU 2013136908 A RU2013136908 A RU 2013136908A RU 2013136908/10 A RU2013136908/10 A RU 2013136908/10A RU 2013136908 A RU2013136908 A RU 2013136908A RU 2013136908 A RU2013136908 A RU 2013136908A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid residue
- seq
- residues
- antibody
- Prior art date
Links
- 125000000539 amino acid group Chemical group 0.000 claims abstract 169
- 239000000427 antigen Substances 0.000 claims abstract 34
- 102000036639 antigens Human genes 0.000 claims abstract 34
- 108091007433 antigens Proteins 0.000 claims abstract 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 35
- 230000000694 effects Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- -1 aromatic amino acid Chemical class 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161460780P | 2011-01-07 | 2011-01-07 | |
| US61/460,780 | 2011-01-07 | ||
| PCT/US2012/020529 WO2012094623A2 (en) | 2011-01-07 | 2012-01-06 | Anti-il-12/il-23 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013136908A true RU2013136908A (ru) | 2015-02-20 |
Family
ID=46457988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013136908/10A RU2013136908A (ru) | 2011-01-07 | 2012-01-06 | Антитела kil-12/il-23 и их применение |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120288494A1 (OSRAM) |
| EP (1) | EP2661448A4 (OSRAM) |
| JP (1) | JP2014506132A (OSRAM) |
| KR (1) | KR20140038369A (OSRAM) |
| CN (1) | CN103596978A (OSRAM) |
| AU (1) | AU2012204237A1 (OSRAM) |
| BR (1) | BR112013017417A2 (OSRAM) |
| CA (1) | CA2821926A1 (OSRAM) |
| MX (1) | MX2013007904A (OSRAM) |
| RU (1) | RU2013136908A (OSRAM) |
| SG (1) | SG191874A1 (OSRAM) |
| TW (1) | TW201242976A (OSRAM) |
| WO (1) | WO2012094623A2 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| MX2009007570A (es) * | 2007-01-16 | 2009-07-22 | Abbott Lab | Metodos para tratar la psoriasis. |
| JP2011515404A (ja) | 2008-03-18 | 2011-05-19 | アボット・ラボラトリーズ | 乾癬を治療するための方法 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP3693007A1 (en) * | 2013-03-15 | 2020-08-12 | Amgen, Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN105749252B (zh) * | 2016-04-29 | 2025-11-14 | 南方医科大学 | Il-9作为治疗血小板缺少症的药物的应用 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| KR20190095931A (ko) | 2016-12-14 | 2019-08-16 | 프로제너티, 인크. | 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료 |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| AU2020320910A1 (en) * | 2019-07-30 | 2022-03-10 | Akeso Biopharma, Inc. | Anti-human p40 protein domain antibody and use thereof |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20250066441A1 (en) | 2021-07-19 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2024086013A1 (en) * | 2022-10-17 | 2024-04-25 | Rani Therapeutics, Llc | Ustekinumab dosage forms and methods |
| WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| ES2251248T3 (es) * | 1998-12-09 | 2006-04-16 | Protein Design Labs, Inc. | Uso de anticuerpos contra il-12 para tratar la psoriasis. |
| US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| CA2525184C (en) * | 2003-05-09 | 2012-10-30 | Centocor, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| AR051805A1 (es) * | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
| EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2009114040A2 (en) * | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
-
2012
- 2012-01-06 AU AU2012204237A patent/AU2012204237A1/en not_active Abandoned
- 2012-01-06 JP JP2013548585A patent/JP2014506132A/ja active Pending
- 2012-01-06 EP EP12732270.9A patent/EP2661448A4/en not_active Withdrawn
- 2012-01-06 SG SG2013052261A patent/SG191874A1/en unknown
- 2012-01-06 TW TW101100711A patent/TW201242976A/zh unknown
- 2012-01-06 KR KR1020137020934A patent/KR20140038369A/ko not_active Withdrawn
- 2012-01-06 MX MX2013007904A patent/MX2013007904A/es not_active Application Discontinuation
- 2012-01-06 CN CN201280004816.0A patent/CN103596978A/zh active Pending
- 2012-01-06 WO PCT/US2012/020529 patent/WO2012094623A2/en not_active Ceased
- 2012-01-06 RU RU2013136908/10A patent/RU2013136908A/ru not_active Application Discontinuation
- 2012-01-06 US US13/374,693 patent/US20120288494A1/en not_active Abandoned
- 2012-01-06 CA CA2821926A patent/CA2821926A1/en not_active Abandoned
- 2012-01-06 BR BR112013017417A patent/BR112013017417A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012094623A3 (en) | 2012-08-30 |
| NZ611840A (en) | 2015-04-24 |
| BR112013017417A2 (pt) | 2016-09-27 |
| CA2821926A1 (en) | 2012-07-12 |
| JP2014506132A (ja) | 2014-03-13 |
| CN103596978A (zh) | 2014-02-19 |
| US20120288494A1 (en) | 2012-11-15 |
| SG191874A1 (en) | 2013-08-30 |
| EP2661448A2 (en) | 2013-11-13 |
| KR20140038369A (ko) | 2014-03-28 |
| AU2012204237A1 (en) | 2013-07-04 |
| EP2661448A4 (en) | 2015-09-16 |
| MX2013007904A (es) | 2013-08-29 |
| TW201242976A (en) | 2012-11-01 |
| WO2012094623A2 (en) | 2012-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013136908A (ru) | Антитела kil-12/il-23 и их применение | |
| JP2014506132A5 (OSRAM) | ||
| US9073999B2 (en) | Anti-IL-17 receptor A neutralizing antibodies | |
| AU2015204674B2 (en) | Antibodies directed against interleukin-33 (IL-33) | |
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| RU2014138499A (ru) | АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FycRIIB | |
| AU2014273966B2 (en) | Oncostatin M receptor antigen binding proteins | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| CA2777691A1 (en) | Monoclonal antibodies to progastrin and their uses | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2015113348A (ru) | Проникающие в клетки пептиды, связывающие интерферон-регулирующий фактор 5 | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| RU2013158625A (ru) | Селективная элиминация эрозийных клеток | |
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| RU2019122648A (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| CN113993534A (zh) | 针对iRhom2的蛋白结合物 | |
| JPWO2019230856A1 (ja) | Ｎａｖ１．７モノクローナル抗体 | |
| RU2014147616A (ru) | Антитела к robo4 | |
| US20210353733A1 (en) | Vaccine and antibody against clostridioides difficile toxin | |
| CN114716542B (zh) | 一种针对新冠病毒刺突蛋白的单克隆抗体及应用 | |
| JP2012523221A5 (OSRAM) | ||
| JP2022119899A (ja) | 新規抗ｐａｄ２抗体 | |
| KR101972899B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질과 C4bp 올리고머화 도메인이 연결된 융합 단백질 및 이의 용도 | |
| US20240287172A1 (en) | Protein binders to irhom2 epitopes | |
| CN113817051B (zh) | 一种抗SARS-CoV-2的单克隆抗体1B6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160615 |